ARVN ARVINAS, INC.
8-K Current Report
Filed: March 18, 2026
Health Care
Pharmaceutical PreparationsARVINAS, INC. (ARVN) 8-K current report filed with SEC EDGAR on March 18, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 7.01: Regulation FD Disclosure
- Item 8.01: Other Events
AI Filing Analysis8-K
Item 7.01 · Regulation FD Disclosure
- • Positive Phase 1 data for ARV-102 showing >50% LRRK2 degradation in cerebrospinal fluid after 28 days in Parkinson’s patients
- • ARV-102 is an oral PROTAC designed to cross the blood-brain barrier targeting LRRK2, a key Parkinson's disease protein
Item 8.01 · Other Events
- • Positive Phase 1 data for ARV-102 showing >50% LRRK2 degradation in CSF of Parkinson’s patients after 28 days treatment
- • ARV-102 well tolerated at 20 mg, 40 mg, 80 mg doses, no serious adverse events or lung function issues observed
Other ARVINAS, INC. 8-K Filings
Get deeper insights on ARVINAS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.